한국비엔씨

256840KOSDAQ기초 의약물질 제조업

54.3 / 100

Reference Date: 2026-06-10

Financial Score17.0 / 40

News Sentiment21.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but PER raises overvaluation concerns. Plunged 23.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Korea BNC is a biotech company established in 2007, specializing in the research, development, and distribution of medical devices, aesthetic equipment, pharmaceuticals, and cosmeceutical products based on hyaluronic acid and collagen. Its main revenue streams include aesthetic medical products (58.2%) and reagents/test equipment (25.2%), with growth driven by global partnerships in the medical and bio sectors.

Number of Employees

295people

Average Salary

49.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

98.25Industry Average 27.710.0Point

3.5x industry avg (risky)

PBR

0.84Industry Average 1.747.0Point

Half of industry avg (excellent)

ROE

0.86Industry Average -6.033.5Point

Well below industry avg

Debt Ratio

9.67Industry Average 6.622.0Point

Higher than industry avg (caution)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.8% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼3.9% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 6.6% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
한국비엔씨 투자한 온코젠, 이중타깃 항암신약 다국가 임상속도
한국비엔씨 관련 투자사인 온코젠의 다국가 임상 진행 가속화로 인해 긍정적인 시장 반응 예상.
Positive
한국비엔씨 투자한 프로앱텍, LYTAC기반 특허출원 "표적단백분해물질....
프로앱텍의 PCT 특허 출원으로 한국비엔씨 관련 투자사의 신약 개발 가능성이 높아져 긍정적 영향 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 2,940Won52-week high 6,05052-week low 2,940

1-month return0.0Point

1m -23.24% (strong drop)

Volume trend5.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15